The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AMLX | +127.88% | N/A | N/A | -24% |
| S&P | +17.53% | +93.66% | +14.13% | +45% |
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 100.0% |
| Gross Profit | -$0.14M | 98.4% |
| Gross Margin | -147.60% | 0.0% |
| Market Cap | $571.39M | 342.2% |
| Market Cap / Employee | $4.65M | 0.0% |
| Employees | 123 | -68.0% |
| Net Income | -$41.44M | 43.0% |
| EBITDA | -$42.72M | 19.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $58.09M | -22.6% |
| Accounts Receivable | $0.10M | -97.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.30M | 586.1% |
| Short Term Debt | $0.67M | -71.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -71.23% | -29.0% |
| Return On Invested Capital | -190.76% | -136.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$25.27M | 62.1% |
| Operating Free Cash Flow | -$25.25M | 62.1% |
| Metric | Q4 2023 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 20.88 | - | |||
| Price to Book | 0.84 | 1.32 | 1.47 | 2.83 | 612.13% |
| Price to Sales | 0.48 | 0.43 | 1.12 | 2.97 | 10.94% |
| Price to Tangible Book Value | 0.84 | 1.32 | 1.47 | 2.83 | 612.13% |
| Price to Free Cash Flow TTM | 95.39 | 12.48 | - | ||
| Enterprise Value to EBITDA | 0.29 | -2.09 | -2.67 | -9.28 | -378.48% |
| Free Cash Flow Yield | 1.0% | 8.0% | - | ||
| Return on Equity | -84.4% | -100.9% | -83.2% | -87.4% | 70.68% |
| Total Debt | $2.57M | $1.98M | $1.38M | $5.96M | 89.81% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
